Physician profile
Devin M Weidman
NPI 1669584157
$5,254.55
in general payments reported to CMS, 2019-2025
13 companies · $3,186 in 2025
The $3,186 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.45 · 2022: $293 · 2023: $258 · 2024: $1,507 · 2025: $3,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,058 · Food and Beverage: $1,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,057.50 |
| Food and Beverage | $1,893.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,367.50 | 2025 | |
| Amgen INC. | $819.61 | 2022-2025 | Evenity, Prolia, Krystexxa |
| Ucb, INC. | $809.35 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $550.21 | 2023-2025 | |
| Abbvie INC. | $378.53 | 2022-2025 | |
| Pfizer INC. | $104.88 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $61.98 | 2024-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $44.40 | 2023-2024 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.35 | 2025 | Ofev |
| Radius Health, INC. | $28.64 | 2025 | Tymlos |
| Csl Behring | $23.17 | 2025 | Hizentra |
| Sobi, INC | $19.97 | 2025 | |
| Lilly USA, LLC | $15.96 | 2024 | Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Weidman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.